The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare ...

Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the ...

J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal ...

The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

A&O Shearman and CMS have emerged as the top legal advisers in terms of deal value and deal volume, respectively.

Wachtell, Lipton, Rosen & Katz and Kirkland & Ellis have emerged as the top M&A legal advisers in North America in terms of ...

Paul Hastings and TriLegal have emerged as the leading mergers and acquisitions (M&A) legal advisers in the Asia-Pacific ...

Goldman Sachs and Houlihan Lokey have emerged as the leading mergers and acquisitions (M&A) financial advisers in North ...

Goldman Sachs and UBS have secured their positions as the leading mergers and acquisitions (M&A) financial advisers in the ...

Bank of America and Rothschild & Co have secured the leading positions as financial advisers in Europe's M&A sector.

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.